Literature DB >> 23796298

Illustrating potential efficiency gains from using cost-effectiveness evidence to reallocate Medicare expenditures.

James D Chambers1, Joanne Lord, Joshua T Cohen, Peter J Neumann, Martin J Buxton.   

Abstract

OBJECTIVES: The Centers for Medicare & Medicaid Services does not explicitly use cost-effectiveness information in national coverage determinations. The objective of this study was to illustrate potential efficiency gains from reallocating Medicare expenditures by using cost-effectiveness information, and the consequences for health gains among Medicare beneficiaries.
METHODS: We included national coverage determinations from 1999 through 2007. Estimates of cost-effectiveness were identified through a literature review. For coverage decisions with an associated cost-effectiveness estimate, we estimated utilization and size of the "unserved" eligible population by using a Medicare claims database (2007) and diagnostic and reimbursement codes. Technology costs originated from the cost-effectiveness literature or were estimated by using reimbursement codes. We illustrated potential aggregate health gains from increasing utilization of dominant interventions (i.e., cost saving and health increasing) and from reallocating expenditures by decreasing investment in cost-ineffective interventions and increasing investment in relatively cost-effective interventions.
RESULTS: Complete information was available for 36 interventions. Increasing investment in dominant interventions alone led to an increase of 270,000 quality-adjusted life-years (QALYs) and savings of $12.9 billion. Reallocation of a broader array of interventions yielded an additional 1.8 million QALYs, approximately 0.17 QALYs per affected Medicare beneficiary. Compared with the distribution of resources prior to reallocation, following reallocation a greater proportion was directed to oncology, diagnostic imaging/tests, and the most prevalent diseases. A smaller proportion of resources went to cardiology, treatments (including drugs, surgeries, and medical devices, as opposed to nontreatments such as preventive services), and the least prevalent diseases.
CONCLUSIONS: Using cost-effectiveness information has the potential to increase the aggregate health of Medicare beneficiaries while maintaining existing spending levels.
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Mesh:

Year:  2013        PMID: 23796298     DOI: 10.1016/j.jval.2013.02.011

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  5 in total

1.  Bilateral Vestibular Deficiency: Quality of Life and Economic Implications.

Authors:  Daniel Q Sun; Bryan K Ward; Yevgeniy R Semenov; John P Carey; Charles C Della Santina
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-06       Impact factor: 6.223

2.  Clinical Indications, Utilization, and Funding of Bariatric Surgery in Europe.

Authors:  Oleg Borisenko; Zeynep Colpan; Bruno Dillemans; Peter Funch-Jensen; Jan Hedenbro; Ahmed R Ahmed
Journal:  Obes Surg       Date:  2015-08       Impact factor: 4.129

3.  Rethinking cost-effectiveness in the era of zero healthcare spending growth.

Authors:  Ronen Arbel; Dan Greenberg
Journal:  Int J Equity Health       Date:  2016-02-24

4.  Innovations in cost-effectiveness analysis that advance equity can expand its use in health policy.

Authors:  Anton L V Avanceña; Lisa A Prosser
Journal:  BMJ Glob Health       Date:  2022-02

Review 5.  Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations.

Authors:  Nathan Wd Lamond; Tallal Younis
Journal:  Int J Womens Health       Date:  2014-05-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.